Previous 10 | Next 10 |
Virgin Galactic Holdings (SPCE) +21% after test flight scheduled for May 22VistaGen Therapeutics (VTGN) +15% after Baird calls stock 'significantly undervalued'.Allogene Therapeutics (ALLO) +13% on positive early-stage data for CAR T candidates in blood cancer.PDS Biotechnology...
- PRIMROSE 1 76-week results confirm PRIMROSE 2 data showing sustained post- treatment effects and evidence of bone mineral density (BMD) recovery following 52 weeks of treatment - - Results c ontinue to support the differentiated profil...
Discovery DISCK +24% on definitive agreement with AT&T.Aerpio Pharmaceuticals ARPO +20% on merger deal with Aadi Bioscience.Nuvve Holding Corp. (NVVE) +16%.Aterian (ATER) +13%.Net Element (NETE) +13%.Mind Medicine MNMD +12% on receiving FDA Type C meeting res...
- Yselty ® for uterine fibroids: US New Drug Application submission planned in Q 3 :21 ; European marketing approval recommendation anticipated in Q4:21 - - Yselty ® for endometriosis: Readou...
GENEVA, Switzerland and BOSTON, MA – May 6 , 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the appointment of Clive Bertram as C...
- EDELWEISS 3 t rial of Yselty ® e xpected to r eport t opline d ata as planned in Q4:21- GENEVA, Switzerland and BOSTON, MA – May 4 , 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBS...
GENEVA, Switzerland and BOSTON, MA – April 30, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN) a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the presentation of five e-Posters o...
- Long-term follow-up study to evaluate bone mineral density in women completing at least 20 weeks of treatment in Phase 3 PRIMROSE 1 or PRIMROSE 2 - GENEVA, Switzerland and BOSTON, MA – April 27 , 2021 – ObsEva SA (NASDAQ:...
Geneva, Switzerland and Boston, MA – April 22 , 202 1 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today published ...
ObsEva ([[OBSV]] +9.3%) has entered into a sales agreement with SVB Leerink to sell the common stock for total gross proceeds of up to $50M, the company has said in a regulatory filing.SVB Leerink will be the sales agent for at the market offering where the company expects to sell the co...
News, Short Squeeze, Breakout and More Instantly...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that the Regulatory ...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that, concurr...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 28 February 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it will wind-down its operati...